Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05952089 · ClinicalTrials.gov registry record · Phase 1

A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart Failure

A Phase 1 study of Heart Failure With Reduced Ejection Fraction, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 1
Development phase
13
Enrollment target
5
Study locations

NCT05952089 is a Phase 1 study of Heart Failure With Reduced Ejection Fraction that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 13 participants, below the 3,965-participant average among 27 other Heart Failure With Reduced Ejection Fraction trials with a reported enrollment target (100% lower). The trial reports 5 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05952089, a Phase 1 study of Heart Failure With Reduced Ejection Fraction, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 1
Development phase
13 participants
Enrollment target
5
Study locations

Study Summary

The purpose of this study is assess the effect of danicamtiv, as an inducer on the drug levels of midazolam in participants with heart failure with reduced ejection fraction (HFrEF).

Conditions Studied

Heart Failure With Reduced Ejection Fraction

Interventions

  • DRUG Midazolam
  • DRUG Danicamtiv

Study Locations (5)

Florida

  • Holy Cross Hospital - Fort Lauderdale
  • Nature Coast Clinical Research - Inverness
  • Jacksonville Center For Clinical Research - Jacksonville

Kentucky

  • Research Integrity LLC - Owensboro

Maryland

  • Sinai Hospital Of Baltimore - Baltimore

Trial Details

FieldValue
Enrollment Target 13 participants
Start Date 2023-08-17
Est. Completion 2024-03-19
Phase Phase 1

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05952089

The ClinicalTrials.gov registry entry for NCT05952089 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,965-participant average among 27 other Heart Failure With Reduced Ejection Fraction trials with a reported enrollment target (100% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Heart Failure With Reduced Ejection Fraction appearing as the primary indexed condition, and to 2 interventions - of which Midazolam is the first listed.

NCT05952089 reports 5 study locations spanning 3 distinct geographic areas - top geographies include Florida, Kentucky, Maryland.

Frequently Asked Questions

What is clinical trial NCT05952089 about?

NCT05952089 is a clinical study titled "A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart Failure". The purpose of this study is assess the effect of danicamtiv, as an inducer on the drug levels of midazolam in participants with heart failure with reduced ejection fraction (HFrEF).

What is the current status of trial NCT05952089?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2023-08-17. Estimated completion is 2024-03-19.

What conditions does trial NCT05952089 study?

This clinical trial studies the following conditions: Heart Failure With Reduced Ejection Fraction.

What interventions are being tested in trial NCT05952089?

The interventions under investigation include: Midazolam (DRUG), Danicamtiv (DRUG).

Who is sponsoring clinical trial NCT05952089?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05952089 being conducted?

This trial has 5 study locations across Florida, Kentucky, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Heart Failure With Reduced Ejection Fraction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Heart Failure With Reduced Ejection Fraction

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.